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Abstract
In various neurological disorders spatio-temporal excitation patterns constitute ex-
amples of excitable behavior emerging from pathological pathways. During migraine,
seizure, and stroke an initially localized pathological state can temporarily spread in-
dicating a transition from non-excitable to excitable behavior. We investigate these
transient wave forms in the generic FitzHugh-Nagumo (FHN) system of excitable
media. Our goal is to define an efficient control minimizing the volume of invaded
tissue. The general point of such a therapeutic optimization is how to apply control
theory in the framework of structures in differential geometry by regarding param-
eter plane M of the FHN system as a differential manifold endowed with a metric.
We suggest to equip M with a metric given by pharmacokinetic-pharmacodynamic
models of drug receptor interaction.
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1 Introduction
Excitability is a central concept in neurophysiology both in health and dis-
ease (Hille, 1997). Under some pathological conditions altered excitability can
spread through the tissue. Such transient wave forms (TWF) occur for exam-
ple in migraine with aura (Lauritzen, 1994; Aurora et al., 1998; Welch, 2005),
epilepsy (Somjen & Aitken, 1984; Giorgi et al., 2006), and stroke (Nedergaard & Astrup,
1986; Hossmann, 1994; Fisher & Takano, 1995; Hakim, 1998; Back, 1998). In
migraine with aura seizure-like activity spreads slowly through parts of the
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cortex. This is observed by symptomatic (Lashley, 1941) and electrophysio-
logical (Hadjikhani et al., 2001) events. Likewise, epileptic seizures can have
a localized onset and then grow in intensity and start to spread. This usu-
ally leads to subsequent generalized motor involvement commonly referred to
as partial seizures with secondary generalization. In some cases, however, the
epileptiform activity may induce changes to subcortical structures produc-
ing clinical signs of general motor involvement that merely mimic a spread
(Schindler et al., 2007). Last but not least, during stroke a cortical region
that surrounds the infarct core and that initially suffers functional injury
can gradually and progressively fail and suffer irreversible structural injury
in untreated patients (Baird et al., 1997). In this condition the electrophysi-
ological changes are persistent, but there exist intermediate repetitive TWF
and it was suggested that ’therapy might [...] target the intermediate forms
of spreading depolarizations so as to protect the penumbra [tissue surround-
ing the infarct core] against recruitment into the infarct core’ (Dreier et al.,
2006). These three paradigmatic clinical manifestations of spreading patholog-
ical states motivate efforts to understand how the spread of such states arises
and how it can be controlled.
The phenotypical manifestation of such spreading pathological states is the
phenomenon of spreading depression (SD) (Lea˜o, 1944). SD is the basis of mi-
graine with aura. Essentially identical electrophysiological features are associ-
ated with infarct expansion, called peri-infarct depolarization (PID) (Mayevsky et al.,
1996; Stru¨mpel et al., 2002; Fabricius et al., 2006). The cascade of events that
produce SD is related to seizures (Kager et al., 2000). Despite certain differ-
ences, seizure events that begin with epileptiform discharges can either termi-
nate in SD, facilitate the synchronization, or spread by a similar mechanism
over a large area with a velocity resembling that of SD (Buresˇ et al., 1974;
Somjen & Aitken, 1984; Gorji & Speckmann, 2004). SD is seizure-like activ-
ity evolving as a slowly spreading non-or-all type process. It is characterized
by the feedback of ion currents that change ion concentrations, which, in
turn, influence the membrane potential (Kager et al., 2000; Somjen, 2001).
Shortly after its onset all neuronal activity is depressed, hence its name.
The name is misleading, because SD can still be observed even when neu-
ronal activity is depressed by blocking the fast transient sodium current INa
(Tobiasz & Nicholson, 1982). SD emerges from an excitable pathway in neu-
ronal tissue independently of the normal neuronal activity. It was therefore
suggested to categorize SD and similar phenomena under the term spreading
depolarizations (Dreier et al., 2006).
There is ample evidence that SD belongs to the self-organization processes due
to the coupling of biochemical reaction with diffusion (Martins-Ferreira et al.,
2000; Dahlem & Chronicle, 2004). Mathematical models of SD have been sug-
gested (Tuckwell & Miura, 1978; Reggia & Montgomery, 1994; Shapiro, 2001;
Kager et al., 2000; Somjen, 2001), though there is not yet consent on the
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mechanism. We will use the spatially extended FitzHugh-Nagumo (FHN) sys-
tem as a generic model of neuronal excitation patterns based on reaction-
diffusion. As a neuronal model, it describes generic pattern formation prop-
erties not limited to nerve impulse propagation along an axon, although it
was originally derived from the Hodgkin-Huxley model of action potentials
(Hodgkin & Huxley, 1952; FitzHugh, 1961; Nagumo et al., 1962). The FHN
system describes also the spatial features of SD wave in neuronal tissue (Dahlem & Mu¨ller,
2004). Furthermore, the transition from non-excitable to excitable media sup-
porting traveling waves was well investigated in the FHN model (Winfree,
1991; Hakim & Karma, 1999). It was suggested that the spatio-temporal pat-
terns in SD occur at this transition (Dahlem & Mu¨ller, 2004). The regime in
which this transition takes place is also well investigated in chemical model
systems in experiment and theory, for a review see (Mikhailov & Showalter,
2006).
The route to spreading depolarizations in a generic model is provided by two
independent pathways: one lowering the threshold of evoked pathological ac-
tivity, the other changing the time scale of biochemical reaction rates, and
hence their time scale ratio. The two pathways might offer new opportunities
in developing optimal therapy. Consider the case that a pathological condi-
tion is caused by a shift along one path whereas therapeutic strategies are
available for both pathways. Suppose both strategies can be combined while
each has individual response rates and side effects. What is an optimal time
efficient combined therapy stopping the spread while minimizing side effects?
Since therapies can be combined, there is a two dimensional manifold in which
therapy takes place. The strategy we suggest is to equip this manifold with a
metric that allows us to find an effective combined therapy with minimal side
effects. Effectiveness is defined by finding a path to a sufficiently low excitabil-
ity where the tissue is not susceptible to spreading events, whereas efficiency
refers to side effects and time.
2 Parameter space of the FHN system
We assume that a standard activator-inhibitor scheme leads to the observed
propagation phenomena during SD. The activator and inhibitor variables, u
and v, are coupled by their kinetic reaction rates f(u, v) and g(u, v), respec-
tively, and can diffuse in the medium. The equations are
∂u
∂t
= f(u, v) +Du
∂2u
∂x2
(1)
∂v
∂t
= ǫg(u, v) +Dv
∂2v
∂x2
.
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Diffusion is represented by diffusion coefficients Du and Dv. By re-scaling
space, the ratio δ = Dv
Du
of the diffusion coefficients can be introduced replac-
ing the parameters Du and Dv. The parameter ǫ is the time scale ratio of
inhibitor and activator variables. The reaction rates f(u, v) and g(u, v) may
possibly be derived from a more complex model of SD, e.g., the one from
Kager et al. (2000), by lumping together all activator variables, such as in-
ward currents and extracellular potassium concentration [K+]o into a single
activator variable and their combined kinetics into a reaction rate f(·, ·). Like-
wise, a single inhibitor variable could be related to recovery processes, such
as effective regulation of [K+]o by the neuron’s Na-K ion pump and the glia-
endothelial system. This will be an important task of future investigations.
We aim to describe universal features of reaction-diffusion coupling that lead
to the onset of spreading pathological states and do not specify the variables
u and v which underly these characteristics other than that they play the
roles of activator and inhibitor, respectively. Their kinetic functions f(u, v)
and g(u, v) are given by the FHN system
f(u, v)= u−
1
3
u3 − v (2)
g(u, v)= u+ β − γv
where β and γ determine the excitation threshold (Fig. 1).
We shall start by viewing the parameter plane of the FHN model as a manifold
M and consider its geometric structure. M has four dimensions (ǫ, β, γ, δ).
In a certain regime the parameters β and γ determine the threshold for a
non-or-all excitation process. Like ǫ, their variation can cause a bifurcation:
the emergence of sustained travelling waves. Instead of the four dimensions
usually a two dimensional subset is investigated to describe this bifurcation, for
example the section at γ = 0.5 (Winfree, 1991), or at γ = 0 (Hakim & Karma,
1999), both with δ = 0. Consider the subset at γ = 0. A particular FHN
system is specified by a point q of this subset. It can be parameterized by the
coordinate functions ǫ(q), i. e., the time scale separation of u and v, and the
threshold parameters β(q). As an alternative coordinate function for β(q)
∆(p) = (β −
1
3
β3) (3)
can be chosen (Hakim & Karma, 1999). While β is a measure of the threshold,
∆ is related to a measure of excitability, because it is equal to the inhibitor
concentration in the steady state (Fig. 1). This is rather a convention than
a definition of excitability. To be more general, we shall only assume that
excitability E is a C∞-function E : U → R in a subset U of M . Further prop-
erties of this function will be defined later. Firstly we want to note that there
obviously exists a whole set of coordinate systems A for M with coordinate
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transformations like Eq. (3) being C∞ diffeomorphisms. Naturally, M can be
identified as a C∞ differential manifold. For a given subset U of dimension
n we can choose the coordinate system ξ = [ξ1, . . . , ξn] = [ξi] ∈ A, with
i ∈ {1, 2, . . . , n} that seems to suit best the purpose of study. For example, in
the section with n=2 and ξ1=ǫ the parameter ξ2 can be chosen either as β or
as ∆. We will consider the hypersection at δ = 0, and γ = 0 and use various
coordinate systems in this submanifold.
3 Transient Wave Forms (TWF)
Excitability is an emergent property of active media. It arises when a critical
parameter value is crossed above which the medium is susceptible for sus-
tained propagating excitation patterns (Mikhailov & Zykov, 1991; Winfree,
1991; Hakim & Karma, 1999; Mihaliuk et al., 2002). In a 1D medium this bor-
der in M is the propagation boundary ∂P . It is obtained by finding solutions
in a co-moving frame in the form u(x, t) = U(y), v(x, t) = V (y), z = x+ ct,
where c is an additional parameter of the unknown wave propagation speed.
Travelling wave solutions in the form of a single pulse are thus equivalent to
the existence of a homoclinic orbit satisfying a system of ordinary differential
equations (Kuznetsov, 1995, p.224 ff). The transition marks a bifurcation of
codimension one. Therefore ∂P is a hypersurface in M separating the regime
supporting travelling waves from the non-excitable one. In a two-dimensional
parameter space, spanned by ǫ, and β or ∆, ∂P is a curve (Fig. 2). Below ∂P
any confined perturbation of arbitrary profile decays eventually. Above ∂P
some wave profiles are stable and travel with constant velocity.
Consider the region close to ∂P , which is referred to as sub-excitable. There
transient wave forms (TWF) exist though sustained waves may not. Note first
that in the absence of a metric in M closeness to ∂P can only be defined with
reference to other borders by which M is further subdivided. The adjacent
bifurcation curve above ∂P is ∂R. It is only defined in systems with more than
one spatial dimension. In these systems ∂R is the border above which open
wave fronts will not disappear because each open end curls in to form a spiral.
Spiral waves rotate and re-enter multiple times the invaded tissue. Below ∂R,
but still above ∂P , TWF exist depending on the initial size of the excitation.
In 2D such waves occur in the shape of particle-like waves (Mihaliuk et al.,
2002), which can be controlled by excitability gradients (Sakurai et al., 2002).
In this study, we investigate the region below ∂P where unstable TWF exist
in the FHN systems with one spatial dimension.
To further subdivide M in the regime below ∂P , we suggest to take the dis-
tance a TWF spreads (Fig. 3b) to define isolines. This distance defines the
volume of tissue at risk (TAR) referring to the risk of transient neurologi-
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cal symptoms or even of permanent damage (PID case) when cortical tissue
is invaded following a local stimulation. At ∂P stable traveling waves exist.
They can invade the whole tissue. Therefore the TAR value is infinite at ∂P .
Below ∂P the value of TAR is finite and rapidly decreases to zero when one
moves the FHN system away from ∂P in parameter space (Fig. 3b-c). We
found the existence of a new boundary ∂S as the TAR value approaches zero.
At this boundary any stimulation profile collapses into the steady state with-
out broadening, that is, without affecting surrounding tissue. ∂S is therefore
contrary to ∂P at which the TAR value is infinite. The region between ∂S
and ∂P is the region where TWF exist in a 1D system. This region defines a
subset U of M . The general point of a therapeutic control strategy is to leave
U by crossing ∂S.
4 Efficient control of transient wave forms
So far excitability E has not been defined. We assume E to be a C∞-function in
U . It is reasonable to assume that E is constant on the two borders, because
these are bifurcation lines at which TAR is constant. Furthermore, since a
change in TAR is suggestive of a change in excitability, we propose both to be
linearly related.
Our goal is to control a path Λ in U along which excitability, and with it the
volume of TAR, is efficiently diminished. Let the path Λ start in U at q where
the neuronal tissue temporarily supports the spread of excitation. Let the path
end on ∂S. Firstly, we assume sufficient knowledge of control characteristics,
e. g., by pharmacokinetic and pharmacodynamic means, as described in the
next section. We will show in the next section that this provides a metric on
U . In this section we will just assume U to be a differential manifold with
a metric. Furthermore, we assume (i) that our control method allows us to
choose any path Λ : I → U parameterized by some interval I ⊂ R, (ii), as
already stated, that E is a C∞-function in a subset U , which includes Λ, and
(iii) that E(q) > E(∂S) holds.
Which path should we take, if we want to reduce excitability by going from q
to ∂S by deliberate control? The efficiency of successful control dragging the
system into the target state p on ∂S should be given by some optimization
criterion. When a metric is given two paths are privileged: the shortest path Λs
between q and ∂S, and also the one that minimizes E by gradient descent. The
latter path Λg implies a metric because covectors like ∂E/∂ξ
j (representing a
gradient) and contravariant vectors (represented by tangent vectors to a path
Λ) are unrelated objects of different kinds. Only a metric tensor gij defines
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the gradient as a tangent vector (using summation convention)
(gradE)i = gij
∂E
∂ξj
. (4)
Therefore, only when a metric is given on U , we can apply some optimization
criterion for the efficient therapeutic path.
5 Metric tensor on U
As efficient control, we proposed in the last section a method based on a
metric structure in U . Therefore, a metric structure is needed to optimize
control. Hence it is natural in this context to endow U with a metric that is
derived by some sort of cost function of the control method. We introduce
a standard pharmacokinetic and pharmacodynamic scheme to illustrate this
concept. Let ζ i be the concentrations of drugs which regulate diverse functions
in populations of neurons. For the sake of simplicity, we neglect the details
of pharmacokinetics as the discipline that describes dosage regimes and the
time-course of ζ i in the body by absorption, distribution, metabolism, and
excretation. We assume the drugs can be constantly administered and their
rate of administrations equals their rate of metabolism and excretion. Thus
ζ i is immediately in its steady state value. Furthermore, we assume that ζ i
follows linear pharmacokinetics. In this situation the steady state of ζ i changes
proportionally according to dose.
The relation between drug dose and response is usually modeled as a hy-
perbolic function assuming a simple drug receptor interaction. Suppose the
response to ζ i is
ξi = ri
(
ξimaxζ
i
EC i50 + ζ
i
)
, (5)
where the ξi define a new coordinate system ξ = [ξ1, . . . , ξn] in U . In this equa-
tion, ri denotes transducer functions that represent the response of the FHN
system to the drug ζ i. For the sake of simplicity we use as transducer functions
ri the identity. EC i50 are the effective doses 50, i.e., doses at which 50% of the
maximal responses ξimax are achieved (Fig. 4a). ξ
i
max is the asymptotic value
of ξi for large concentrations.
In analogy with Eq. (3), where we have introduced the new coordinate ∆, we
have thus introduced the coordinate system ζ ∈ A as new control parameters
of the FHN system. A new coordinate system with a known metric is needed
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as a reference system from which the metric in U is obtained by coordinate
transformation. Let us denote the components of the metric tensor of U in
the coordinate system ζ as gij. Above we have introduced the new coordinate
system ξ ∈ A of the response variables. The components of the metric tensor
in this coordinate system (ξ) are then
g˜αβ =
∂ζ i
∂ξα
gij
∂ζj
∂ξβ
. (6)
Likewise, we can calculate the unknown components gij from g˜ij. The coordi-
nate system ζ is a privileged reference system for U by selecting ζ i. However,
this does not imply that it is Cartesian (g˜ij = δij , δij being the Kronecker
delta tensor representing the Euclidean metric in Cartesian coordinates), as is
readily seen since the choice of concentration units is arbitrary. For example,
commonly the logarithm of the concentration ζ i is plotted on the abscissa,
as shown in Fig. 4a. Hence the question is whether a structure of the phar-
macodynamic scheme can be natural choice treated as a metric structure in
differential geometry defining g˜ij.
Suppose that ζ i or one of their metabolites have toxic side effects. Their dose
response curve follows the same relation as Eq. (5), although shifted to the
right on the dose axis by a higher toxic dose 50 (TC50)
T i = ti
(
T imaxζ
i
TC i50 + ζ
i
)
. (7)
ti denotes transducer functions that represent the response of the toxic system.
Again for the sake of simplicity we use as transducer functions ti the identity
function. In analogy to Eq. (6) we obtain
g˜αβ =
∂ζ i
∂ξα
∂T k
∂ζ i
δkl
∂T l
∂ζj
∂ζj
∂ξβ
, (8)
assuming T = [T 1, . . . , T n] builds a Cartesian coordinate system of the costs
with the Euclidean metric δkl. The association of the cost coordinate system
(T ) with the Cartesian one is a naturally choice, since the efficiency of control
is–by definition–measured in these costs.
We end this section with one example that to some extent corresponds to a
subtype of migraine with aura. For this subtype a novel pathogenic genetic
mutation was found. Therefore, at least in principle, the route to hyperex-
citability was discovered on a molecular level. A recent migraine study by
Vanmolkot et al. (2007) showed a mutation in the gene coding the sodium
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channel that leads to a slowed-down inactivation and a two-fold faster recov-
ery from inactivation. In our simplified FHN system this is modeled by slowed
inhibition, i. e., lower ǫ values. As a consequence, the physiological state (N,
Fig. 4d) of the cortex is shifted into hyperexcitable state (). By definition, the
physiological state (N) is on a lower TAR-level than the hyperexcitable state
(). The therapeutic goal would be to shift the cortical state back to low a
TAR-level, at which the pathological activity, i. e., the neurological symptoms,
do not spread.
To begin with, we need to specify dose response and toxicity curves. They
are chosen arbitrarily to complete the example but without direct relation to
the above mentioned subtype of migraine. Suppose that we have a drug with
concentration ζ1 acting exclusively on ǫ (e. g., ξ1 ≡ ǫ). Its dose response graph
is shown in Fig. 4b. It is similar to the one in Fig. 4a but rotated such that the
response axis corresponds to the ǫ-axis. Let another drug ζ2 act exclusively
on β (e. g., ξ2 ≡ β). Its dose response graph is shown in Fig. 4c. It is mirrored
(from Fig. 4a) such that the response axis corresponds to the β-axis. For the
sake of readability we replace the set {1, 2} of indices i by {ǫ, β} and use ζ i
for both the drug concentration and the drug name. Let the effective doses 50
EC i50 be the same for both (without loss of generality we choose EC
i
50 = 0.1),
and let the toxic doses 50 TC i50 differ. Usually TC
i
50 is several times higher
then the effective dose. We choose TCǫ50 = 5 and TC
β
50 = 10. The drug ζ
β
has therefore a relatively higher therapeutic index TI i = TC i50/EC
i
50 than
ζǫ. Furthermore, we assume that both drugs have a sufficient efficacy, that is,
they are each potent enough to drag the FHN system back to it physiological
excitability defined by the TAR-isoline (Fig. 4d). The maximal response rates
(ξimax) for both are chosen such that already 80% of ξ
i
max is effective. Likewise
and again without loss of generality we fix T imax at ξ
i
max.
Given the example described above, we can calculate the cost for individual
and combined therapy. If exclusively drug ζβ is administered to control ex-
citability, the FHN system moves in parameter space along the β-axis (down-
wards in Fig. 4d) until the physiological TAR level (TAR low) is reached. The
toxicity imposed by the therapeutic benefit in this case is 3.85% of the max-
imal toxic level of T β. An exclusive administration of drug ζǫ (which has a
only half the therapeutic index TIǫ compared to TIβ) cost 7.4% of the max-
imal toxic level T ǫ. This corresponds to a shift from point marked with  to
the point marked with N in Fig. 4d. At last, we consider how the two drugs
must be administered in a combined therapy. An optimal combined therapy
reaches the physiological TAR level at 1.84% of the maximal combined toxic
level Ttot = T
ǫ+T β (see the two black lines starting at (•) and terminating at
the both effect axes in Fig. 4b and d). Due to the nonlinearity in the response
and toxcity curves the total cost of the combined theraby is much less than
the average of the individual therapies.
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6 Discussion
The phenotypical scheme of cortical spreading depression describes transient
waves of massive depolarization of neurons and astrocytes. Such a spreading
depolarization (Dreier et al., 2006) is associated with migraine, epilepsy and
stroke. Their etiologies are mainly discussed in the context of hyperexcitability
and disorders known as channelopathies, that is, diseases caused by a mutation
in gene coding for ion channels. The challenge is to bridge the gap between
the molecular level of the cause and macroscopic tissue level of the effects.
We suggest that there are at least two independed routes towards a hyperex-
citable state that supports transient wave forms in cortical tissue: one chang-
ing the ratio of kinetic rates and one lowering the threshold. While the latter
route changes the nullclines, the former changes only the trajectories in the
phase space. Consequently, there are also two routes out of the hyperexcitable
regime. This is of particular interest when a critical therapeutic time window
exits in which the volume of affected tissue is largely increased, as for exam-
ple in peri-infarct depolarization. Then the therapeutic aim would be first to
prevent tissue loss within the given therapeutic time window and re-establish
the physiological value later. In Fig. 4d this would correspond to a path from
the hyperexcitable state () directly to a state of low tissue at risk (•) and
from there back to the physiological state (N).
We have described efficient control of excitability by a simple pharmaco-
dynamic model. In general, the study of beneficial effects of independent
pathways is complicated by numerous interactions between pharmacokinet-
ics, pharmacodynamics, and homeostatic factors and by individual variability.
For example, the introduction of antagonistic behavior between ζǫ and ζβ will
complicate the geometrical structure of U . In general the coordinate system of
the costs [T 1, . . . , T n] will not build a Cartesian coordinate system. However,
if we have a mapping from general costs and effects defined by Eqs. (5) and
(7) we still can infer a metric structure of the parameter space of FHN.
In conclusion, as a first step to implement the proposed control strategy ac-
curate estimates given by pharmacokinetic-pharmacodynamic models of drug
activity are needed for the regime of transient wave forms. We want to stress
this point, namely that this estimates must be obtained in the regime of tran-
sient wave forms, that is, a regime close to a bifurcation. Attempts to obtain
estimates of pharmacokinetic-pharmacodynamic parameters in the regime far
from this bifurcation will probably lead to inaccurate results. Then the next
step is to construct an appropriate metric on the differential manifold of the
parameter space in order to optimize the path from the hyperexcitable state
back to the physiological state.
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Fig. 1. The nullclines (bold) u˙ = 0 and v˙ = 0 in the phase space of the homogeneous
FHN system with γ = 0, β = 1.4. Their intersection at (us, vs) is a stable fixed point.
Three trajectories are drawn for ǫ = 0.04: one canard trajectory (dotted), passing
through the maximum of the nullisocline u˙ = 0, and two trajectories starting at
v = vs nearby but on opposite sides of the canard trajectory. They diverge sharply,
producing threshold behavior: (dashed) = super-threshold and (dashed-dotted) =
sub-threshold stimulation. The parameter β correlates with the threshold size, while
∆ is in a certain range inversely related and therefore correlates with the excitability
of the system (see text).
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Fig. 2. Parameter space of the FHN system (γ = 0, δ = 0). Besides the parameter
ǫ, a threshold parameter β and an excitability parameter ∆ is used in (a) and (b),
respectively, to span the parameter space (see Fig. 1). Three regimes exist defined
by the spatio-temporal patterns that occur: waves, transient wave forms (TWF)
and no spreading activity. The arrows mark two paths which are perpendicular to
the border ∂S in (a) but not in (b).
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Fig. 3. (a) Parameter space with tissue-at-risk(TAR)-isolines (dashed). The extent
a TWF spreads is defined from the stimulation border to the location where the
maximum activator concentration u lies above the nullisocline u˙ = 0 (inset). The
red curve in the inset is the projection of a TWF from the infinite phase space
of the space-dependent FHN system into the one of the homogeneous system for
β = 1.4, ǫ = 0.04. The projection is taken at the moment which we defined as
the collapse of the TWF. (b)-(d) Space-time plots of the transient wave forms
(TWF) following a stimulation (increase of u by 2 for 0 < x < 1, starting from
the fixed point). Parameters: (b) ǫ = 0.04, β = 1.4, (c) ǫ = 0.05, β = 1.4, (d)
ǫ = 0.095, β = 1.185. Du = 1 and δ = 0 for all parts. The color code denotes the
activator u as defined in the inset of panel (a).
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Fig. 4. (a) Dose response curves for an effective dose and a toxic dose with the
typical sigmoidal shape caused by the logarithmic scaling. (b),(c) Same as in (a),
but with rotated and inverted axes for two drugs ζǫ acting on ǫ and ζβ acting on β.
(d) Schematic parameter space with two TAR-isolines (TAR high and TAR low). A
route to hyperexcitability can be caused by a shift in ǫ (from N to ). The optimum
path from the hyperexcitable state () towards the isoline of the physiological state
(TAR low) using the two dose and toxic response curves in (b) and (c) leads to (•).
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